Suggested remit: To appraise the clinical and cost effectiveness of clostridium botulinum neurotoxin type A within its marketing authorisation for treating hypersalivation associated with neurological conditions.
Status In progress
Process STA 2018
ID number 1150

Provisional Schedule

Committee meeting: 2 19 September 2019
Expected publication 09 October 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Merz Pharma UK (clostridium botulinum neurotoxin type A)
Others Department of Health
  NHS Canterbury and Coastal CCG
  NHS England
  NHS High Weald Lewes Havens CCG
  Welsh Government
Patient carer groups Action Cerebral Palsy
  Brain and Spine Foundation
  Different Strokes
  Leonard Cheshire Disability
  Motor Neurone Disease Association
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Neurological Alliance
  Parkinson’s UK
  Stroke Association
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The Brain Charity
  The Pace Centre
Professional groups Association of British Neurologists
  Association of Neuroscience Nurses
  British Association of Stroke Physicians
  British Geriatrics Society
  British Neuropathological Society
  British Neuropsychiatry Association
  British Paediatric Neurology Association (BPNA)
  British Society of Rehabilitative Medicine
  Chartered Society of Physiotherapy
  College of Occupational Therapists
  Institute of Neurology
  Neuromodulation Society of UK and Ireland
  Primary Care Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Speech and Language Therapists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Health Forum
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurses Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (glycopyrronium bromide)
  Concordia International (glycopyrronium bromide)
  Genus Pharmaceuticals (trihexyphenidyl hydrochloride)
  Martindale Pharma (glycopyrronium bromide, transdermal hyoscine hydrobromide)
  Proveca (glycopyrronium bromide)
  Relevant research groups
  Brain Research Trust
  British Neurological Research Trust
  Cochrane Cystic Fibrosis and Genetic Disorders Group
  Cochrane Movement Disorders Group
  Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  Cochrane Stroke Group
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research
  The Cure Parkinson’s Trust
  The Society for Research in Rehabilitation
  UK Parkinson’s Disease Consortium
  Wellcome Trust
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Multiple Sclerosis Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
24 July 2019 Committee meeting: 1
23 November 2018 Invitation to participate
14 September 2018 Please note that following on from information provided by the company the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late November 2018.
20 July 2018 In progress, Referral
12 March 2018 (10:00) Scoping workshop (London)
25 January 2018 - 22 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance